We are all in for better health, everywhere.

Good health should never be a privilege, dependent on your wealth or where you live in the world. This is a passionately held belief, behind which we all unite at Teva. It's also the inspiration behind the work that we do for patients, as a global leader in generics and biopharmaceuticals with a strong innovative portfolio.

We’re committed to continuing our long legacy of finding new ways to make quality medicines more affordable and accessible to more people. As it stands today, our portfolio of generic and innovative products is among the largest of any pharmaceutical company in the world serving nearly 200 million patients every single day.

We’re leading the way with generic medicines

We’re proud to be the world’s leading manufacturer of generic medicines, having played a key role in developing the industry over the last 40 years. However, if you’re wondering what exactly generics are, take a look at the video below.

Biopharmaceuticals: the next generation of innovative medicines

As we look for new ways to deliver better health around the world, we’re increasing our investment in research and operations to support our growing portfolio of innovative medicines and biopharmaceutical products.

Made from living cells or organisms, biologic and biosimilar medicines advance treatment options for patients and have the potential to deliver precise, personalized treatments.

We currently have five biopharmaceuticals on the market and approximately 20 original biologic and biosimilar programs in various stages of development. Many of these will be produced in our new biopharmaceutical plant in Ulm, Germany. Take a look behind the scenes of this state-of-the-art facility, in the video below.

Innovative leadership, focused on core therapeutic areas

We’re committed to developing and delivering life-enhancing treatments across a wide range of therapeutic areas. We’re especially proud to be the second largest global supplier of medicines on the World Health Organization’s Essential Medicines List for respiratory conditions, as well as being one of the top five global suppliers of oncology treatments.

Alongside these key therapeutic areas, our innovative research and development team are focused on making treatments more accessible for patients suffering from migraines, headaches and pain, and neurodegenerative conditions.

Environmental, Social and Governance (ESG):
Making a difference where it matters most

At Teva, we are united by our unique opportunity to make a meaningful impact on society and the world. We enhance access to essential medicines for people—no matter where they live. We respect the environment in our operations and supply chain, including by increasing renewable energy use and reducing greenhouse gas emissions. We promote the health and well-being of our people and foster an environment where everyone belongs and all opinions are valued. And we do business the right way—with integrity and transparency, always.

As of 2022, we’ve launched five access to medicines programs that bring our products to vulnerable populations who otherwise would not be able to get them—and we’ll launch three more by 2025. Take a look at the video below to see how we’re working closely with Global Hope (Haematology Oncology Paediatric Excellence) to bring critical medicines to children living with cancer across Africa:

ESG is everyone's business at Teva - it's how we care for our patients, our planet and each other.

Advancing access to essential medicines is at the heart of our mission. We are focused on fulfilling it by becoming a committed global health partner, addressing unmet needs, increasing the reach of affordable medicines, and expanding our generic and innovative medicines portfolio.

Additionally, we’re playing a key role in helping overcome the other great crisis facing the world today: climate change. Our commitments to both include:

• Issuing a $5 billion sustainability-linked bond (SLB), the first ever to be linked to both access to medicines and environmental targets
   
• Donating $487 million worth of medicines (307 million doses) in 2021 to patients in low- and middle-income countries
   
• Reducing direct greenhouse gas emissions by 25% by 2025